Document is current
Any future updates will be listed below
-
Authors
Hu, Yan https://orcid.org/0000-0002-8435-6586
Horlbeck, Max A. https://orcid.org/0000-0002-3875-871X
Zhang, Ruochi https://orcid.org/0000-0002-1103-5044
Ma, Sai https://orcid.org/0000-0002-9785-7929
Shrestha, Rojesh
Kartha, Vinay K.
Duarte, Fabiana M.
Hock, Conrad
Savage, Rachel E.
Labade, Ajay https://orcid.org/0000-0003-1348-8220
Kletzien, Heidi
Meliki, Alia
Castillo, Andrew
Durand, Neva C. https://orcid.org/0009-0006-5647-2623
Mattei, Eugenio https://orcid.org/0000-0002-8889-658X
Anderson, Lauren J. https://orcid.org/0009-0001-5180-6122
Tay, Tristan
Earl, Andrew S. https://orcid.org/0000-0002-5732-954X
Shoresh, Noam
Epstein, Charles B. https://orcid.org/0000-0001-8358-8345
Wagers, Amy J.
Buenrostro, Jason D. https://orcid.org/0000-0001-9958-3987
- License Information
-
More Information
Article History
Received: 12 October 2022
Accepted: 22 November 2024
First Online: 22 January 2025
Competing interests
: J.D.B. holds patents related to ATAC–seq, is a consultant for the Treehouse Family Foundation, and is a SAB member of Camp4 and seqWell. J.D.B. and S.M. hold a patent based on SHARE–seq. M.A.H. holds patents related to CRISPR-mediated interference and activation, and is a consultant for Akuous, Inc., DEM Biopharma and Gordian Biotechnology. A.J.W. is a scientific advisor for Frequency Therapeutics and Kate Therapeutics, is also a cofounder and scientific advisory board member and holds private equity in Elevian, Inc., a company that aims to develop medicines to restore regenerative capacity. Elevian also provides sponsored research to the Wagers laboratory. The other authors declare no competing interests.
